Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcino...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

JimmyOcarri Aug. 17 at 7:47 PM

$BCAB $YAAS $AIFA $SILO $GURE swing

0 · Reply

SFG1 Aug. 17 at 5:15 PM

$BCAB I will add sub $3.00......I am only a buyer

0 · Reply

biovaluable Aug. 17 at 1:06 PM

$BCAB warning delisting they have no money.

1 · Reply

Zen__Trades Aug. 16 at 11:46 PM

Hanging my hat on $IPST this week for the early win. I'm expecting continuation or pullback followed by momentum. From the mid to high $2's this has ten-bagger potential. Simply no other chart like this one heading into Monday. I need $RAIN to confirm bottom. When it bases I will scale. There is a big trade waiting there but I need to see it start turning around. $KIDZ is almost there too. $BCAB is another post-ER slump that could start curling next week. These can be great little trades as long as you allow hem to confirm bottom before entry. Good luck all.

0 · Reply

biovaluable Aug. 15 at 10:27 AM

$BCAB stock manipulayion by shortage

0 · Reply

biovaluable Aug. 14 at 10:20 PM

$BCAB j is scammer

0 · Reply

gregwiseman Aug. 14 at 7:39 PM

$BCAB the company is in bancruptcy , its just a matter of time . they are trying to delay as long as they can , why ? the company has no employees any more they reduced more than 70% but now the money is over. its just a matter of time to chapter 7

2 · Reply

Digfog Aug. 14 at 5:52 PM

$BCAB over 550 million scammed to date, not too shabby Jay. Do you think satan will ease his hoof into his arse or does he slam it in when the time comes? I feel for the folks in the trials who were sold a magic bag of beans.

0 · Reply

SFG1 Aug. 14 at 5:40 PM

$BCAB Lowest price since RS....$3.04

0 · Reply

biovaluable Aug. 14 at 2:11 PM

$BCAB they have no money

0 · Reply

BioAtla Quarterly report: Q2 2026

Jun 3, 2026, 8:00 AM EDT - 2 months ago

BioAtla Proxy statement: Proxy filing

Jun 3, 2026, 8:00 AM EDT - 2 months ago

BioAtla Proxy statement: Proxy filing

2026-05-18T10:54:19.000Z - 3 months ago

Context Therapeutics enters license agreement amendment with BioAtla

CNTX

May 15, 2026, 4:00 PM EDT - 3 months ago

BioAtla Quarterly report: Q1 2026

2026-04-02T23:50:53.000Z - 4 months ago

BioAtla trading halted, news pending

2026-03-31T20:45:40.000Z - 5 months ago

BioAtla announces 50-for-1 share consolidation

Mar 31, 2026, 4:06 PM EDT - 5 months ago

BioAtla Announces Share Consolidation

Mar 31, 2026, 4:05 PM EDT - 5 months ago

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 31, 2026, 7:00 AM EDT - 5 months ago

BioAtla Annual report: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 5 months ago

BioAtla Slides: Investor presentation

Mar 2, 2026, 7:30 AM EST - 6 months ago

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Mar 2, 2026, 7:00 AM EST - 6 months ago

BioAtla Proxy statement: Proxy Filing

Feb 11, 2026, 7:00 AM EST - 6 months ago

BioAtla Proxy statement: Proxy Filing

Jan 30, 2026, 7:00 AM EST - 7 months ago

BioAtla Proxy statement: Proxy Filing

Jan 16, 2026, 7:00 AM EST - 7 months ago

BioAtla Registration statement: Registration Filing

Jan 15, 2026, 7:00 AM EST - 7 months ago

BioAtla Proxy statement: Proxy Filing

Dec 31, 2025, 7:00 AM EST - 8 months ago

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Dec 31, 2025, 7:00 AM EST - 8 months ago

BioAtla Proxy statement: Proxy Filing

Dec 5, 2025, 7:00 AM EST - 9 months ago

BioAtla Proxy statement: Proxy Filing

Nov 24, 2025, 7:00 AM EST - 9 months ago

BioAtla Proxy statement: Proxy Filing

Nov 21, 2025, 12:25 AM EST - 9 months ago

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

BioAtla Slides: Q3 2025

Nov 13, 2025, 4:05 PM EST - 9 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 10 months ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 10 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 10 months ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 10 months ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 11 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

BioAtla Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 1 year ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 1 year ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 7, 2025, 10:00 AM EDT - 1 year ago

BioAtla Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q1 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

May 6, 2025, 8:00 AM EDT - 1 year ago

BioAtla Registration statement: Registration Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Proxy statement: Proxy Filing

Apr 23, 2025, 10:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 5:05 PM EDT - 1 year ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 1 year ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 1 year ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 1 year ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Earnings release: Q3 2024

Oct 4, 2024, 9:05 AM EDT - 2 years ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 2 years ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 2 years ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Sep 9, 2024, 7:00 AM EDT - 2 years ago

BioAtla Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q2 2024

Jul 25, 2024, 5:39 PM EDT - 2 years ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Jun 5, 2024, 8:00 AM EDT - 2 years ago

BioAtla Transcript: Jefferies 2024 Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 2 years ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q1 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 13, 2024, 9:30 AM EDT - 2 years ago

BioAtla Transcript: The Citizens JMP Life Sciences Conference

May 8, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

Apr 24, 2024, 4:35 PM EDT - 2 years ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 2 years ago

BioAtla Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

BioAtla Proxy statement: Proxy Filing

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Annual report: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q4 2023

Mar 26, 2024, 4:01 PM EDT - 2 years ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 19, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 7, 2024, 8:00 AM EST - 2 years ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Jan 11, 2024, 12:45 PM EST - 2 years ago

BioAtla Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Dec 20, 2023, 8:00 AM EST - 2 years ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 2 years ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 6, 2023, 1:00 PM EST - 2 years ago

BioAtla Transcript: The JMP Securities Hematology and Oncology Summit

Dec 6, 2023, 8:00 AM EST - 2 years ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 5, 2023, 8:00 AM EST - 2 years ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Nov 30, 2023, 8:00 AM EST - 2 years ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 28, 2023, 8:00 AM EST - 2 years ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

JimmyOcarri Aug. 17 at 7:47 PM

$BCAB $YAAS $AIFA $SILO $GURE swing

0 · Reply

SFG1 Aug. 17 at 5:15 PM

$BCAB I will add sub $3.00......I am only a buyer

0 · Reply

biovaluable Aug. 17 at 1:06 PM

$BCAB warning delisting they have no money.

1 · Reply

Zen__Trades Aug. 16 at 11:46 PM

0 · Reply

biovaluable Aug. 15 at 10:27 AM

$BCAB stock manipulayion by shortage

0 · Reply

biovaluable Aug. 14 at 10:20 PM

$BCAB j is scammer

0 · Reply

gregwiseman Aug. 14 at 7:39 PM

2 · Reply

Digfog Aug. 14 at 5:52 PM

0 · Reply

SFG1 Aug. 14 at 5:40 PM

$BCAB Lowest price since RS....$3.04

0 · Reply

biovaluable Aug. 14 at 2:11 PM

$BCAB they have no money

0 · Reply

StocktwitsEarnings Aug. 13 at 10:20 PM

$BCAB Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.27 up 101.69% YoY • Reported revenue of $6.5M

0 · Reply

Digfog Aug. 13 at 9:16 PM

$BCAB 👀

0 · Reply

biovaluable Aug. 13 at 2:17 PM

$BCAB where is epcam data j? Are u short.?

1 · Reply

biovaluable Aug. 12 at 8:26 PM

$BCAB more short chinese scam do not believe pankoo

0 · Reply

Digfog Aug. 7 at 8:25 PM

$BCAB poor BCAB, it can’t even attract the good pumpers anymore. That being said I can’t help to think something is up. Good or bad who knows but the silence and complete withdrawal of any science news is curious to say the least. ✌️

0 · Reply

pankooo Aug. 7 at 3:36 PM

$BCAB hold

1 · Reply

JA1950 Aug. 7 at 11:28 AM

$HOWL @BiotechValues PART I: Not to be combative, but you reference ChatGPT analysis in a post below and I would just offer that I asked it to contrast the value of Howl's assets against those of $BCAB as an AI exercise. My question was generic and unbiased. And should be taken with more than a grain of salt. ChatGPT's response: Why I think BCAB could command the larger premium Several factors differentiate BioAtla: Breadth of the platform. CAB technology is applicable across multiple antibody modalities, creating more optionality than a cytokine-focused platform. Pipeline diversity. BCAB has multiple distinct assets (ADCs plus a conditionally active T-cell engager), whereas HOWL's programs are more concentrated around cytokine biology.

2 · Reply

roedel09 Aug. 5 at 1:46 PM

$BCAB 👀

0 · Reply

biovaluable Aug. 5 at 7:10 AM

$BCAB short position at $3.35 go hell J!

0 · Reply

Moonlightcat Aug. 4 at 6:03 PM

$BCAB zero value

0 · Reply

Toptradersam Aug. 4 at 9:14 AM

$ENSC $PLTR $BLE $BCAB $AMRC Check out today's stock pick, along with the technical setup and key price levels I'm watching. https://www.youtube.com/watch?v=r7euykJNlFc

0 · Reply

Market Cap	5.07M
Revenue (ttm)	2.00M
Net Income (ttm)	-59.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,980.50%
Debt to Equity Ratio	0.00

Volume	30,200
Avg Vol	57,666
Day's Range	N/A - N/A
Shares Out	1.66M
Stochastic %K	41%
Beta	0.78
Analysts	Hold
Price Target	$10.00